Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEGPH20 with Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
NCT02715804Phase 3Terminated
- Sponsor
- Halozyme Therapeutics, Inc.
- Start
- Mar 2016
- Primary completion
- Nov 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 22
01
Overview
A Phase 3 trial of pegvorhyaluronidase alfa in pancreatic ductal adenocarcinoma (PDAC), sponsored by Halozyme Therapeutics, Inc.. Started Mar 2016; status: terminated.
02
Drugs
pegvorhyaluronidase alfa
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02715804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02715804.